Park, Jae H. http://orcid.org/0000-0002-2903-5130
Nath, Karthik
Devlin, Sean M. http://orcid.org/0000-0002-6801-720X
Sauter, Craig S.
Palomba, M. Lia http://orcid.org/0000-0001-5099-9156
Shah, Gunjan
Dahi, Parastoo
Lin, Richard J. http://orcid.org/0000-0002-0834-7880
Scordo, Michael
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Shouval, Roni
Tomas, Ana Alarcon http://orcid.org/0000-0002-6290-1061
Cathcart, Elizabeth
Mead, Elena
Santomasso, Bianca http://orcid.org/0000-0001-9423-4059
Holodny, Andrei http://orcid.org/0000-0002-1159-2705
Brentjens, Renier J. http://orcid.org/0000-0002-3364-5388
Riviere, Isabelle
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Article History
Received: 26 February 2023
Accepted: 17 May 2023
First Online: 3 July 2023
Competing interests
: J.H.P. received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Inc., Curocel, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi and Takeda; received honoraria from OncLive, Physician Education Resource, and MJH Life Sciences; serves on scientific advisory board of Allogene Therapeutics and Artiva Biotherapeutics; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier and Takeda. C.S.S. has served as a paid consultant to Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK; serves on DSMBs for Ono Pharmaceuticals and CRISPR Therapeutics; and has received research funds for clinical trials from Juno Therapeutics, Celgene/BMS, Bristol Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. M.L.P. received consulting fees from BMS, Cellectar, Kite, Mustang Bio and Synthekine. G.S. received consulting fees from Amgen, BMS, Beyond Spring, and Janssen and serves on DSMB for Arcellx. P.D. received consulting fees from Kite. R.J.L. received consulting fees from Kite and Priothera. M.S. served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., Kite and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation and Amgen, Inc.; and has received honoraria from i3Health and Medscape for CME-related activity. M.-A.P. reports personal fees from Adicet, Allovir, Caribou Biosciences, Celgene, BMS, Equilium, Exevir, Karyopharm, Merck, MorphoSys, Omeros, Syncopation, VectivBio AG, Vor Biopharma, Cidara Therapeutics, Medigene, Sellas Life Sciences and NexImmune; personal fees and other support from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis; and other support from OrcaBio outside the submitted work. B.S. is an inventor on United States Provisional Patent Application No. US20210181179A1 ‘Diagnosis and treatment of immunotherapy-induced neurotoxicity’ filed by Memorial Sloan Kettering Cancer Center and served in a consulting or advisory role for Celgene, Janssen, Legend Biotech, Incyte, Kite/Gilead and In8bio. A.H. is an owner/president of fMRI Consultants, LLC. R.J.B. has licensed intellectual property to and collected royalties from BMS, Caribou and Sanofi; received research funding from BMS; is a consultant to BMS, Atara Biotherapeutics Inc., CoImmune and Triumvira; was a consultant for Gracell Biotechnologies Inc but ended employment in the past 30 months; and is a member of the scientific advisory board for CoImmune and Triumvira. I.R. reports grants from Takeda Pharmaceuticals and Atara, personal fees from Mnemo Therapeutics, Akron, the Centre for Commercialization of Cancer and Oribiotech, and other support from Bristol Myers Squibb outside the submitted work. M.S. reports grants from Atara Biotherapeutics outside the submitted work, as well as patent 8389282 issued and licensed to Juno Therapeutics, patent 11242375 issued and licensed to Atara Biotherapeutics, patent 10370452 issued, licensed and with royalties paid from Fate Therapeutics, patent 11377637 issued and licensed to Takeda Pharmaceuticals, patent 11377637 issued and licensed to Mnemo Therapeutics, and patent 11377637 issued and licensed to Minerva Biotechnologies. The remaining authors declare no competing interests.